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Abstract Four stereoisomers of 2-norbornyl-N–n-butylc-
arbamates are characterized as the pseudo substrate inhibi-
tors of cholesterol esterase. Cholesterol esterase shows
enantioselective inhibition for enantiomers of exo- and endo-
2-norbornyl-N–n-butylcarbamates. For the inhibitions by
(R)-(?)- and (S)-(-)-exo-2-norbornyl-N–n-butylcarbamates,
the R-enantiomer is 6.8 times more potent than the S-enantio-
mer. For the inhibitions by (R)-(?)- and (S)-(-)-endo-2-nor-
bornyl-N–n-butyl-carbamates, the S-enantiomer is 4.6 times
more potent than the R-enantiomer. The enzyme-inhibitor
complex models have been proposed to explain these different
enantioselectivities.
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1 Introduction
Cholesterol esterase (CEase, EC 3.1.1.13) also known as
bile salt-activated lipase, carboxyl ester lipase, lysophos-
pholipase, and non-specific lipase, is responsible for the
hydrolysis of dietary cholesterol esters, fat soluble vitamin
esters, phospholipids and triacylglycerols. Like the serine
proteases, CEase possesses a catalytic triad, Ser194-
His435-Asp320, that serves as a nucleophilic and general
acid–base catalytic entity [12, 14, 22]. Two X-ray struc-
tures of CEase have been reported [4, 23]. Although dif-
ferent bile salt-activation mechanisms are proposed, the
active site of CEase from two different X-ray crystal
structures is similar to that of lipases.
CEase has also been demonstrated that it is involved
directly in lipoprotein metabolism, in that the enzyme
catalyzes the conversion of large low-density lipoprotein
(LDL) to smaller, denser, more cholesterol ester-rich
lipoproteins, and that the enzyme may regulate serum
cholesterol levels [3]. Therefore, the ability of CEase to
convert large LDL to smaller LDL subspecies, and the
relationship between plasma CEase and LDL levels, sug-
gest that high plasma CEase levels may constitute a
potential risk factor for atherosclerosis. Thus, CEase
inhibitors may be suitable for the treatment of combined
lipoprotein disorders characterized by elevation of choles-
terol [1, 7, 15, 19].
Carbamate inhibitors have been characterized as the
pseudo substrate inhibitors of CEase (Scheme 1) [9–11].
We have synthesized (R)-(?)-exo-, (S)-(-)-exo-, (R)-(?)-
endo-, and (S)-(-)-endo-2-norbornyl-N–n-butylcarbamates
(Fig. 1) from optically pure (R)-(?)-exo-, (S)-(-)-exo-,
(R)-(?)-endo-, and (S)-(-)-endo-2-norborneols which are
kinetically resolved by porcine pancreatic lipase in
organic solvent (Schemes 2, 3, 4) [5, 6]. (R)-(?)-exo-,
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(S)-(-)-exo-, (R)-(?)-endo-, and (S)-(-)-endo-2-Norbornyl
N–n-butylcarbamates have shown high enantioselectivity for
the inhibition of acetylcholinesterase and butyrylcholinest-
erase. In this paper, we further study the stereoselectivity
for cholesterol esterase inhibition by these chiral norbornyl-
derived carbamates.
2 Materials and Methods
2.1 Materials
Porcine pancreatic lipase (PPL), porcine pancreatic CEase,
p-nitrophenyl butyrate (PNPB), and triton-X 100 (TX)
were obtained from Sigma. (±)-exo- and (±)-endo-2-
Norborneol, n-butyl isocyanate, triethylamine, CDCl3, tet-
ramethylsilane, t-butyl methyl ether, butanol, vinyl acetate,
butyryl chloride, pyridine, and (S)-(?)-a-methoxy-a-tri-
fluoromethylphenylacetyl chloride were purchased from
Aldrich (USA). Silica gel and TLC plate were obtained
from Merck (Germany). Hexane, CH2Cl2, ethyl acetate,
and tetrahydrofuran were obtained from TEDIA (USA).
Sodium dihydrogen phosphate (NaH2PO4:2H2O), disodium
hydrogen phosphate (Na2HPO4:12H2O), hydrogen chloride
(HCl), sodium hydroxide (NaOH), potassium hydroxide
(KOH), calcium chloride (CaCl2), and sodium chloride
(NaCl) were purchased from UCW (Taiwan). Ethanol
(95%) was obtained from Taiwan Tobacco & Liquid
Corporation (Taiwan). All other chemicals were of the
highest purity available commercially.
2.2 Synthesis of Inhibitors
2.2.1 Kinetic resolution of (S)-(-)-exo- and (R)-(?)-exo-
2-norborneol (Scheme 2) [5, 6])
To a t-butyl methyl ether (100 mL) solution of racemic (±)-
exo-2-norbornyl butyrate (1.82 g, 10 mmol) (synthesis from
condensation of (±)-exo-2-norborneol with 1.2 eqs. of
butyryl chloride in the presence of pyridine in CH2Cl2,
90–95% yield), porcine pancreatic lipase (4 g) was added.
The reaction mixture was shaken at 36 C at 200 rpm for
72 h. The reaction mixture was evaporated to dryness and
was poured into a silica gel column. The product (S)-(-)-
exo-2-norborneol (549 mg, 4.9 mmol) and recovered unre-
active (R)-exo-2-norbornyl butyrate (930 mg, 5.1 mmol) were
separated by liquid chromatography eluted by hexane–ethyl
acetate solvent gradient. This reaction yielded (S)-(-)-exo-2-
norborneol (49% yield) (mp = 125–126 C and [a]D25 =
-2.70o; [a]D
25 = -3.07o and mp = 126–127 C from litera-
ture) [2, 13, 16, 24, 25] and recovered unreactive (R)-exo-2-
norbornyl butyrate (51% yield). (R)-(?)-exo-2-Norborneol
(mp = 125–126 C and [a]D25 = ? 2.70o) ([a]D25 = ? 3.06o
and mp = 126–127 C from literature) was obtained from
basic hydrolysis (0.1 M KOH) of (R)-exo-norbornyl butyrate in
ethanol (95% v/v) in 99% yield. To a 0.1 M KOH ethanol
(95% v/v) solution (50 mL), (R)-exo-2-norbornyl butyrate
(500 mg, 2.75 mmol), was added and stirred at 25 C for 18 h.
The reaction mixture was evaporated to dryness and was
poured into a silica gel column. The product (R)-(?)-exo-2-
norborneol (300 mg, 2.7 mmol) was isolated from liquid
chromatography by hexane–ethyl acetate solvent gradient in
99% yield.
The enantiomeric excess (e.e.) values of (R)-(?)-exo-
and (S)-(-)-exo-2-norborneols from the resolutions were
calculated to be 80 and 84%, respectively, from the 19F
NMR spectra of their Mosher’s esters as the followings
(Table 1) [8, 20, 21]. In an NMR tube containing 1 mL of
CDCl3, (R)-(?)-exo-2-norborneol (5.6 mg, 50 lmol) was
condensed with the Mosher’s chiral derivatizing agent
(S)-(?)-a-methoxy-a-trifluoromethyl-phenylacetyl chloride
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Scheme 1 Kinetic scheme for pseudo substrate inhibitions of CEase
by carbamate inhibitors in the presence of substrate. E: enzyme,
CEase; E-A: acyl enzyme; EI: enzyme-inhibitor Michaelis complex;
E-I0: carbamyl enzyme; ES: enzyme-substrate Michaelis complex;
I: pseudo substrate inhibitor; k2: carbamyl constant; k3: decarbamy-
lation constant; ka: acylation constant; kcat: turnover number = kakd/
(ka ? kd); kd: deacylation constant; Ki: inhibition constant; Km:
Michaelis–Menten constant; P: product, 2-norborneol; P0: product,
p-nitrophenol; P0 0: product, butyrate; Q: product, butylcarbamic acid;
S: substrate, PNPB
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Fig. 1 Structures of (R)-(?)-exo-, (S)-(-)-exo-, (R)-(?)-endo-,
(S)-(-)-endo-2-norbornyl-N–n-butylcarbamates
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[8] (12.6 mg, 50 lmol) in CDCl3 in the presence of
pyridine (10 lL) at 25 C for 24 h (Scheme 4). The
fluorine chemical shifts at -73.948 and -74.113 ppm
with the integration ratio of 9/1 were assigned to be the
fluorine atoms of (R)- and (S)-exo-2-norbornyl-(S)-a-
methoxy-a-trifluoromethylphenyl acetates, respectively.
The enantiomeric excess of (R)-(?)-exo-2-norborneol
from the kinetic resolution by lipase catalysis was cal-
culated to be 80% from integration of these two 19F NMR
peaks (Table 1).
The enantiomeric excess of (S)-(?)-exo-2-norborneol
from the kinetic resolution by lipase catalysis was calcu-
lated to be 84% in a similar method described for (R)-(-)-
exo-2-norborneol (Table 1).
2.2.2 Kinetic resolution of (S)-(-)-endo- and (R)-(?)-
endo-2-norborneol (Scheme 3) [5, 6]
To a t-butyl methyl ether (50 mL) solution of racemic (±)-
endo-2-norborneol (5 g, 44.6 mmol) and vinyl acetate
rac-exo-2-norborneol
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O
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Scheme 2 Kinetic resolution of
(R)-(?)- and (S)-(-)-exo-2-
norborneols from lipase
catalyzed hydrolysis of racemic
(±)-exo-2-norbornyl butyrate
rac-endo-2-norborneol
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Scheme 3 Kinetic resolution of
(R)-(?)- and (S)-(-)-endo-2-
norborneols from lipase
catalyzed acetylation of racemic
(±)-exo-2-norborneol with vinyl
acetate
OH
(+)-(2R)-exo-norborneol
O
(2R)-exo-norbornyl-(S)-α-methoxy-α-trifluoro
methylphenylacetate
OH
(-)-(2S)-exo-norborneol
O
Cl OCH3
CF3
(+)-(S)-α-methoxy-α-trifluoro
methylphenylacetyl chloride
+
O OCH3
CF3NaH
THF
OO
Cl OCH3
CF3
(+)-(S)-α-methoxy-α-trifluoro
methylphenylacetyl chloride
+
O OCH3
CF3NaH
THF
(2S)-exo-norbornyl-(S)-α-methoxy-α-trifluoro
methylphenylacetate
Scheme 4 Determination of
enantiomeric excess and
absolute configuration of
(R)-(?)- and (S)-(-)-exo-2-
norborneols by 19F NMR
spectra of their Mosher’s ester
derivatives
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(9.34 g, 108.6 mmol), porcine pancreatic lipase (30 g) was
added. The reaction mixture was shaken at 37 C at
200 rpm for 72 h. The reaction mixture was evaporated to
dryness and was poured into a silica gel column. The
product (R)-(?)-endo-2-norbornyl acetate (3.36 g, 21.8 mmol)
and recovered unreactive (S)-(-)-endo-norborneol (2.55 g,
22.7 mmol) were separated by liquid chromatography
eluted by hexane–ethyl acetate solvent gradient. This
reaction yielded (R)-(?)-endo-2-norbornyl acetate (49%)
and recovered unreactive (S)-(-)-endo- norborneol (51%)
(mp = 148–150 C and [a]D25 = -1.81o; mp = 151–152 C
and [a]D
25 = -1.89o from literature) [2, 13, 16, 24, 25].
(R)-(?)-endo-2-Norborneol (mp = 148–150 C and [a]D25 =
? 1.81; [a]D
25 = ? 1.89o and mp = 151–152 C from liter-
ature) was obtained from basic hydrolysis (0.1 M KOH) of
(R)-endo-norbornyl acetate in ethanol (95%) in 99% yield. To
a 0.1 M KOH ethanol (95% v/v) solution (50 mL), (R)-(?)-
endo-2-norbornyl acetate (3 g, 19.4 mmol), was added and
stirred at 25 C for 18 h. The reaction mixture was evapo-
rated to dryness and was poured into a silica gel column. The
product (R)-(?)- endo-2-norborneol (2.16 g, 19.3 mmol) was
isolated from liquid chromatography by hexane–ethyl acetate
solvent gradient in 99% yield. The enantiomeric excess (e.e.)
values of (S)-(-)-endo- and (R)-(?)-endo-2-norborneols from
the resolutions were calculated to be 90 and 92%, respec-
tively, from the 19F NMR spectra of their Mosher’s esters
(Table 1).
In an NMR tube containing 1 mL of CDCl3, (R)-(?)-
endo-2-norborneol (5.6 mg, 50 lmol) was condensed with
the Mosher’s chiral derivatizing agent (S)-(?)-a-methoxy-
a-trifluoromethylphenylacetyl chloride (12.6 mg, 50 lmol)
in CDCl3 in the presence of pyridine (10 lL) at 25 C for
24 h. The fluorine chemical shifts at -73.975 and
-74.152 ppm with the integration ratio of 95/5 were
assigned to be the fluorine atoms of (2R)- and (2S)-endo-
norbornyl-(S)-a-methoxy-a-trifluoromethylphenyl acetates,
respectively. Therefore, the enantiomeric excess of (R)-
(?)-endo-2-norborneol from the kinetic resolution by
lipase catalysis was calculated to be 90% from integration
of these two peaks (Table 1).
The enantiomeric excess of (S)-(-)-endo-2-norborneol
from the kinetic resolution by lipase catalysis was calcu-
lated to be 92% in a similar method described for (R)-(?)-
endo-2-norborneol (Table 1).
2.2.3 Synthesis of (R)-(?)-exo-, (S)-(-)-exo-, (R)-(?)-
endo-, and (S)-(-)-endo- 2-norbornyl-N–n-
butylcarbamates
(R)-(?)-exo-, (S)-(-)-exo-, (R)-(?)-endo-, and (S)-(-)-
endo-2-norbornyl-N–n-butylcarbamates (800 mg, 3.8 mmol)
were synthesized from condensation of optically pure (R)-
(?)-exo-, (S)-(-)-exo-, (R)-(?)-endo-, and (S)-(-)-endo-2-
norborneols (500 mg, 4.46 mmol), respectively, with 1.2
eqs. of n-butyl isocyanate (5.36 mmol) in the presence of 1.2
eqs. of triethylamine (5.36 mmol) in tetrahydrofuran (50 mL) at
25o C for 1 day (85–92% yield). All products were purified by
liquid chromatography (silica gel, hexane–ethyl acetate) and
were characterized by 1H and 13C NMR spectra, mass spectra,
and elemental analysis as the followings.
(R)-(?)-exo-and(S)-(-)-exo-2-norbornyl-N–n-butycarbamates.
1H NMR (CDCl3) d 0.92 (t, J = 7 Hz, 3H, carbamate
x-CH3), 1.40 (sextet, J = 7 Hz, 2H, carbamate c-CH2),
1.0–1.6 (m, 7H, 4,5,6,7-norbornyl Hs), 1.56 (quintet,
J = 7 Hz, 2H, carbamate b-CH2), 1.70 (m, 1H, norbornyl
C(1)H), 2.24 (m, 2H, norbornyl C(3)H2), 3.15 (t, J = 7 Hz,
2H, carbamate a-CH2), 4.53 (m, 1H, norbornyl-C(2)H).
13C
NMR (CDCl3) d 13.7 (carbamate x-CH3), 19.9 (carbamate
b-CH2), 24.2 (norbornyl C-6), 28.1 (norbornyl C-5), 32.1
(carbamate c-CH2), 35.2 (norbornyl C-7), 35.3 (norbornyl
C-4), 39.6 (norbornyl C-3), 40.6 (norbornyl C-1), 41.6
(carbamate a-CH2), 77.7 (norbornyl C-2), 156.4 (carba-
mate C=O). Mass spectra, exact mass: 211.157; elemental
analysis: calculated for C12H21NO2: C, 68.21; H, 10.02; N,
6.63, found C, 68.15; H, 10.32; N, 6.56. mp 178–180 C)
(decomp.).
(R)-(?)-endo- and (S)-(-)-endo-2-norbornyl-N–n-butycarbamates.
1H NMR (CDCl3) d 0.92 (t, J = 7 Hz, 3H, carbamate
x-CH3), 1.20–1.80 (m, 11H, carbamate b- and c-CH2 and
4,5,6,7-norbornyl Hs), 1.96 (m, 1H, norbornyl C(1)H),
Table 1 Enantiomeric excess (%) and optical purity (%) for the kinetic resolution of racemic exo-2-norborneol and endo-2-norborneol by lipase
in organic solvent
Compound Enantiomeric excess (%)a Optical purity (%)b
(R)-(?)-exo-2-norborneol 80 88
(S)-(-)-exo–2-norborneol 84 90
(R)-(?)-endo-2-norborneol 90 96
(S)-(-)-endo-2-norborneol 92 96
a Enantiomeric excess (%) was calculated from ratio of integration of fluorine chemical shift of their Mosher’s ester derivatives of 19F NMR
spectra (Scheme 4)
b Optical purity (%) was calculated as 100 9 [a] D
25
observed/[a] D
25
literature
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2.10–2.50 (m, 2H, norbornyl C(3)H2), 3.19 (t, J = 7 Hz,
2H, carbamate a-CH2), 4.60 (br. s, 1H, carbamate NH),
4.89 (m, 1H, norbornyl-C(2)H). 13C NMR (CDCl3) d 13.7
(carbamate x-CH3), 19.8 (carbamate b-CH2), 20.9 (nor-
bornyl C-6), 29.4 (norbornyl C-5), 32.1 (carbamate c-CH2),
36.4 (norbornyl C-7), 36.9 (norbornyl C-4), 37.2 (norbor-
nyl C-3), 40.4 (carbamate a-CH2), 40.7 (norbornyl C-1),
75.7 (norbornyl C-2), 156.8 (carbamate C=O). Mass
spectra, exact mass: 211.157; elemental analysis: calcu-
lated for C12H21NO2: C, 68.21; H, 10.02; N, 6.63, found C,
68.17; H, 10.30; N, 6.58. mp 178–180 C (decomp.).
2.3 Instrumental Methods
All steady state kinetic data were obtained from an
UV–visible spectrophotometer (Agilent 8453) with a cell
holder circulated with a water bath. 1H, 13C, and 19F NMR
spectra were recorded in CDCl3 at 400, 100, and 377 MHz,
respectively, with an internal reference tetramethylsilane
(TMS) at 25 C on a Varian Gemini 400 spectrometer.
Mass spectra were recorded at 71 eV in a mass spec-
trometer (Joel JMS-SX/SX 102A). Elemental analyses
were preformed on a Heraeus instrument. Optical rotation
was recorded on a polarimeter (Perkin-Elmer 241).
2.4 Data Reduction
Origin (version 6.0) was used for linear and nonlinear least-
squares curve fittings.
2.5 CEase Inhibition
CEase inhibition reactions were determined as described
by Hosie et al. [9–11]. CEase-catalyzed hydrolysis of
PNPB in the presence of a carbamate inhibitor was fol-
lowed continuously at 410 nm on the UV–visible spec-
trometer. The temperature was maintained at 25.0 C by a
refrigerated circulating water bath. All reactions were
preformed in sodium phosphate buffer (1 mL, 0.1 M, pH
7.0) containing NaCl (0.1 M), CH3CN (2% by volume),
detergent triton-X 100 (TX) (0.5% by weight), substrate
PNPB (0.1 mM), and varying concentration of the inhibi-
tors. Requisite volumes of stock solution of substrate
PNPB and the inhibitor in acetonitrile were injected into
reaction buffer via a pipet. CEase was dissolved in
sodium phosphate buffer (0.1 M, pH 7.0). There was no
pre-incubation of inhibitor and enzyme. The reaction was
followed until 85% of substrate consumption was
completed. Carbamate inhibitors (R)-(?)-exo-, (S)-(-)-
exo-, racemic-(±)-exo-, (R)-(?)-endo-, (S)-(-)-endo- and
racemic-(±)-endo-2- norbornyl-N–n-butylcarbamates were
characterized as the pseudo or alternate substrate inhibitors
of CEase (Scheme 1) [9–11, 17, 18]. The carbamylation
stage was rapid compared to subsequent decarbamylation
(k2 k3), thus the two steps are easily resolved kinetically.
The apparent inhibition constant (1 ? [S]/Km) Ki and car-
bamylation constant (k2) were obtained from the nonlinear
least-squares curve fitting of the kapp vs. [I] plot against
Eq. (1) (Fig. 2). The inhibition constant Ki was then cal-
culated form the apparent inhibition constant when both
[S] and Km values for the CEase-catalyzed hydrolysis of
PNPB were known (Table 2). The Km value for the CEase
catalyzed hydrolysis of PNPB was 100 ± 20 lM obtained
from Michaelis–Menten equation. The bimolecular rate
constant, ki = k2/Ki, was related to overall inhibitory
potency.
kapp ¼ k2 I½ = Ki 1 þ S½ =Kmð Þ þ I½ ð Þ ð1Þ
In the presence of a carbamate inhibitor, time courses
for hydrolysis of PNPB are biphasic, and kapp values can be
calculated as Eq. (2) [9–11].
A ¼ A0 þ vo  vssð Þ 1  exp kappt
  
=kapp þ vsst ð2Þ
In Eq. (2), A0, kapp, vo, and vss are the absorbance at t = 0,
the observed first-order inhibition rate constant, the initial
velocity, and the steady-state velocity, respectively. Once
kapp values have been determined as various inhibitor
concentrations, the resulting data are fit to Eq. (1) to obtain
Ki and k2 values. The carbamylation stage is rapid com-
pared to subsequent decarbamylation (k2 [[ k3), thus the
two stages are easily resolved kinetically.
Duplicate sets of data were collected for each inhibitor
concentration.
2.6 Molecular Modeling
Molecular structures of (R)-(?)- and (S)-(-)-exo-2-nor-
bornyl- N–n-butylcarbamates and (R)-(?)- and (S)-(-)-
endo-2-norbornyl-N–n-butylcarbamates shown in Fig. 3
were depicted from the molecular structures after MM-2
energy minimization (minimum root mean square gradient
was set to be 0.01) by CS Chem 3D (version 6.0).
3 Results and Discussion
3.1 Synthesis of (R)-(?)–exo-, (S)-(-)-exo-, (R)-(?)-
endo-, and (S)-(-)-endo-2-norbornyl-N–n-
butylcarbamates
(R)-(?)-exo-, (S)-(-)-exo-, (R)-(?)-endo-, and (S)-(-)-
endo-2-Norborneols have been resolved by porcine pan-
creatic lipase in organic solvent (Schemes II & III) [6, 7].
The high amount of porcine pancreatic lipase used in these
resolutions is due to the fact that porcine pancreatic lipase
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catalytic rate in organic solvent is very slow. But isolation
of product from the reaction mixture is easy for the enzyme
reaction in organic solvent. The absolute configurations of
(S)-(-)-exo-, (R)-(?)-exo- (Scheme 4), (S)-(-)-endo-, and
(R)-(?)-endo-2-norborneols are determined on the basis of
their optical rotation values and the 19F NMR spectra of
their Mosher’s ester derivatives (Table 1).
Stereoisomers of (R)-(?)-exo-, (S)-(-)-exo-, (R)-(?)-
endo-, and (S)-(-)-endo-2-norbornyl-N–n-butylcarbamates
are synthesized from optically pure (R)-(?)-exo-, (S)-(-)-
exo-, (R)-(?)-endo-, and (S)-(-)-endo-2-norborneols.
3.1.1 2-Norbonyl-N–n-butylcarbamates Act as Pseudo
Substrate Inhibitors of Cholesterol Esterase
The mechanism for CEase-catalyzed hydrolysis of sub-
strate involves formation of the noncovalent enzyme-sub-
strate Michaelis complex, followed by nucleophilic attack
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Fig. 2 Nonlinear least-squares curve fittings of kapp vs. inhibitor
concentration ([I]) plot against Eq. (1) for the pseudo-substrate
inhibition [9–11] of CEase by a (S)-(-)-exo-2-norbornyl-N–n-
butylcarbamate, b (R)-(?)-exo-2-norbornyl-N–n-butylcarbamate,
c (S)-(-)-endo-2-norbornyl-N–n-butylcarbamate, and d. (R)-(?)-
endo-2-norbornyl-N–n-butylcarbamates. The parameters of the fit
were a k2 = 0.0011 ± 0.0001 s
-1, Ki = 2.5 ± 0.5 lM, and R =
0.96995; b k2 = 0.0011 ± 0.0001 s
-1, Ki = 0.4 ± 0.1 lM, and
R = 0.96862; c k2 = 0.0025 ± 0.0001 s
-1, Ki = 1.3 ± 0.5 lM,
and R = 0.97909; and d k2 = 0.0037 ± 0.0001 s
-1, Ki = 9 ± 2 lM,
and R = 0.99099. CEase-catalyzed hydrolysis of PNPB in the
presence of carbamate was followed continuously at 410 nm on the
UV–visible spectrometer at 25.0 C. All reactions were preformed in
sodium phosphate buffer (1 mL, 0.1 M, pH 7.0) containing NaCl
(0.1 M), CH3CN (2% by volume), detergent triton-X 100 (TX) (0.5%
by weight), substrate PNPB (0.1 mM), and varying concentration of
the inhibitors
Table 2 The k2, Ki and ki values of the CEase inhibitions by 2-norbornyl carbamates
Inhibitors Ki (lM) k2 (10
-3 s-1) ki (10
3 M-1 s-1) Enantioselecitivity
(R)-(?)-exo- 0.4 ± 0.1 1.1 ± 0.1 3 ± 1 6.8
(S)-(-)-exo- 2.5 ± 0.5 1.1 ± 0.1 0.44 ± 0.08 1.0
rac-(±)-exo- 1.7 ± 0.1 1.2 ± 0.1 0.70 ± 0.07 1.6
(R)-(?)-endo- 9 ± 2 3.7 ± 0.1 0.41 ± 0.09 1.0
(S)-(-)-endo- 1.3 ± 0.5 2.5 ± 0.1 1.9 ± 0.7 4.6
rac-(±)-exo- 5 ± 1 3.2 ± 0.2 0.6 ± 0.1 1.5
Ki (1 ? [S]/Km) values were obtained from the nonlinear least-squares curve fittings of kapp vs. [I] plot against Eq. (1) (Fig. 2) where
[PNPB] = 100 lM and the Km value for the CEase catalyzed hydrolysis of PNPB was 100 ± 20 lM which was calculated from Michaelis–
Menten equation in the absence of any pseudo or alternate substrate inhibitor. The ki values were calculated from k2/Ki and uncertainty in ki
values = {(uncertainty of k2)
2 ? (uncertainty of Ki)
2}1/2
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of the active site serine on the substrate, which leads to the
acyl enzyme intermediate; hydrolysis of the acylenzyme
completes the catalytic cycle (Scheme 1). In the presence
of substrate, carbamates serve as the pseudo or alternate
substrates inhibitors of CEase [9–11, 17, 18]. Accordingly,
the carbamate inhibitors (Fig. 1) are characterized and the
inhibition data are summarized in Table 2.
The first step for this pseudo substrate inhibition is
reversible formation of the noncovalent enzyme-inhibitor
complex, with inhibition constant Ki. Subsequent attack of
serine residue of the enzyme on the carbamate carbonyl
carbon of the inhibitor forms the carbamylenzyme, with
rate constant k2. The carbamate group of the inhibitor must
bind to the acyl group binding site of the active site [4, 23],
which is located deeply inside the enzyme. The third step is
decarbamylation, governed by k3.
3.2 Enantioselectivity for the CEase inhibitions
by (R)-(?)- and (S)-(-)-exo-2-norbornyl-N–n-
butylcarbamates (Table 2, Fig. 3a)
For the CEase inhibitions by (R)-(?)- and (S)-(-)-exo-2-nor-
bornyl- N–n-butylcarbamates, R-enantiomer is 6.8 times more
potent than S-enantiomer (Table 2). Therefore, CEase shows
high enantioselectivity for (R)-(?)-exo-2-norbornyl- N–n-bu-
tylcarbamates over (S)-(-)-exo-2-norbornyl-N–n-butylcarba-
mate. Modeling both (R)-(?)-exo- and (S)-(-)-exo-2-
norbornyl-N–n-butylcarbamates into the active site of CEase
[4, 23] indicates that the norbornyl ring of (R)-(?)-exo-2-nor-
bornyl-N–n-butylcarbamate is fitting well into the cholesteryl
binding site of the enzyme (Fig. 3a). On the other hand, the
norbornyl ring of (S)-(-)-exo-2-norbornyl-N–n-butylcarba-
mate is repulsive to Ser 194 and His 435 of the catalytic triad.
This repulsion may create an unfavorable interaction between
(S)-(-)-exo-2-norbornyl-N–n-butylcarbamate and the enzyme
and make this inhibitor a less potent one.
When two most potent inhibitors (R)-(?)-exo-2-norbornyl-
N–n-butylcarbamate and (S)-(-)-endo-2-norbornyl-N–n-bu-
tylcarbamate are compared, the norbornyl ring of R-exo isomer
(Fig. 3b) is much closer to cholesteryl moiety of cholesterol
ester than that of S-endo isomer (Fig. 3a). Therefore, the highly
favorable interaction between the norbornyl ring of the inhibitor
and the cholesteryl group binding site of the enzyme makes (R)-
(?)-exo-2-norbornyl-N–n-butylcarbamate become the most
potent inhibitors among four stereoisomers of 2-norbornyl-N–
n-butylcarbamates (Table 2).
3.3 Enantioselectivity for the CEase inhibitions by
(R)-(?)- and (S)-(-)-endo-2-norbornyl-N–n-
butylcarbamates (Table 2, Fig. 3b)
For the PSL inhibitions by (R)-(?)- and (S)-(-)-endo-2-
norbornyl-N–n-butylcarbamates, the S-enantiomer is 4.6
times more potent than the R-enantiomer (Table 2).
Therefore, CEase shows high stereoselectivity for (S)-(-)-
endo-2- norbornyl-N–n-butylcarbamates over (R)-(?)-endo-
2-norbornyl-N–n-butylcarbamate from a similar reason
(Fig. 3b).
4 Conclusion
The stereoselectivity of CEase with respect to norbornyl-
derived carbamates can be demonstrated for the first time.
Among the four stereoisomers of the 2-norbornyl-N–n-bu-
tylcarbamates, (R)-(?)-exo-stereoisomer is the best inhibi-
tor. It can therefore be concluded that unfavorable
repulsions diminish the affinity when the exo-substituted
inhibitor is (S)-configurated at the norbornyl moiety. For the
endo-derivatives, an opposite conclusion can be drawn.
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Fig. 3 Superimposition of (A) (R)-(?)- and (S)-(-)-endo-2-norbor-
nyl-N–n-butylcarbamates, (B) (R)-(?)- and (S)-(-)-exo-2-norbornyl-
N–n-butylcarbamates, and cholesterol ester at their carbamyl moieties
or acyl group into the acyl group binding site of CEase [4, 23]. R-exo
isomer is a more potent inhibitor than S-exo isomer due to an
unfavorable, repulsive interaction between the norbornyl ring of S-exo
isomer and the catalytic triad Ser 194. S-endo isomer is a more potent
inhibitor than R-endo isomer due to an unfavorable, repulsive
interaction between the norbornyl ring of R-endo isomer and the
catalytic triad Ser 194
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